EX-99.1 2 tmci-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2026 Financial Results PONTE VEDRA, Fla. - August 7, 2026 - Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights • Generated revenue of $45.4 million in the second quarter 2026 compared to $47.4 million in the same period in 2025. • Reported second quarter 2026 net loss of $(15.9) million and adjusted EBITDA of $(3.5) million in the second quarter 2026. • Reduced year-to-date cash usage by 57% or $3.6 million when compared to the same period in 2025. Cash, cash equivalents, and marketable securities totaled $45.6 million as of June 30, 2026. • Initiated limited market release of SuperBite™ Compression Screw System and completed the first surgical case with HyperPlate™ XM Dynamic Compression Locking Implant System. • Increased adoption of expanded bunion portfolio with approximately 40% of Lapiplasty® surgeon users incorporating one or m…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Treace Medical Concepts, Inc.
TMCINASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 7, 2026, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.…
Company context
Treace Medical Concepts, Inc. is a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and related deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System - a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for